In Business news

Follow this topic

Bookmark

Record learning outcomes

Sanofi has announced the sale of a 50 per cent controlling stake of Opella to US private equity firm Clayton, Dubilier & Rice (CD&R) for 10 billion Euros, making Opella a standalone company.

Sanofi is keeping a significant interest in Opella through a 48.2 per cent shareholding, with Bpifrance owning a 1.8% stake.

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 manufacturing sites and four science and innovation development centres. With a portfolio of brands, such as Allevia, Dulcolax, Buscopan and Cialis Together, Opella is the third-largest business worldwide in the over the counter and vitamins, minerals & supplements market.

Julie Van Ongevalle, Opella president and CEO, said: “Going independent is not just a milestone. It is our moment. I am proud of our talented team of 11,000 who made this happen. With the right partners and a sharp focus, we are set to reshape how people everywhere manage their health.”

Nick Linton,head of Opella UK: “Self-care in the UK is being redefined — fast. The responsibility for health is shifting, and people are stepping up. At Opella UK, we’re not just responding to that change — we’re driving it. This announcement marks our moment of independence, and we’re using it as a launchpad to innovate harder, connect deeper, and move faster.”

David Taylor takes on the role of chairman of Opella's supervisory board. He is a former chairman and CEO of Procter & Gamble, and current chairman of the Board of Delta and senior advisor to CD&R funds.